Welcome to our dedicated page for Baird Medical SEC filings (Ticker: BDMD), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Baird Medical Investment Holdings Ltd (NASDAQ: BDMD) SEC filings page on Stock Titan is designed to help investors and researchers review the company’s regulatory disclosures alongside AI-generated insights. Baird Medical operates in the medical devices segment of the healthcare sector and focuses on minimally invasive diagnostics and treatment, including microwave ablation technology for benign and malignant tumors.
When available, annual reports on Form 10-K and quarterly reports on Form 10-Q can provide details about Baird Medical’s business, risk factors, and discussion of operations. For a medical device company, these filings may include information on product lines such as microwave ablation systems, geographic markets, regulatory considerations, and research and development activities related to minimally invasive surgical instruments and surgical robotic systems.
Current reports on Form 8-K, when filed, can disclose significant corporate events, such as material agreements, changes related to manufacturing arrangements, or key developments in commercialization strategies. Proxy statements may address topics such as governance and executive compensation, which can be relevant for shareholders tracking BDMD stock.
Stock Titan enhances access to these documents with AI-powered summaries that highlight important sections and explain complex regulatory language in more accessible terms. As forms such as 10-K, 10-Q, 8-K, and, when applicable, Form 4 insider transaction reports are made available through EDGAR, they are surfaced here with real-time updates and concise AI explanations to support more efficient review of Baird Medical’s regulatory history.
Baird Medical Investment Holdings Limited filed its annual Form 20-F as a Cayman Islands holding company whose operations are conducted through PRC subsidiaries. The report highlights that dividends and cash movements depend heavily on these subsidiaries and are subject to PRC foreign exchange and reserve restrictions.
The company details extensive PRC regulatory licensing for its Class III microwave ablation equipment and needles and a Class II biopsy needle, plus a Manufacture License for Class II and III medical devices valid to May 24, 2026. It discusses reliance on a concentrated distributor and customer base, third-party suppliers, and marketing service providers.
Key risks include evolving PRC healthcare regulation, the Holding Foreign Companies Accountable Act and possible Nasdaq delisting if PCAOB access is lost, prior compliance issues such as a lapsed manufacturing license and underpaid social insurance, dependence on tender processes and medical insurance reimbursement, and challenges in product development, clinical trials, and competition.
Baird Medical Investment Holdings Ltd director Xu Lijian filed an initial statement of beneficial ownership. The filing reports direct ownership of 25,000 RSU Shares (BDMD), indicating Xu’s equity position in the company through restricted stock unit shares.
Baird Medical Investment Holdings Ltd director Qiu Quan has filed an initial Form 3, formally registering as a reporting person for BDMD. The structured data shows no reported purchases, sales, or other transactions and no derivative positions in this initial ownership statement.
Baird Medical Investment Holdings Ltd submitted a Form 3 identifying Lu Rongjian as an officer of the company with the title Chief Technical Officer. The structured data shows no reported share transactions, derivative positions, or holding entries associated with this reporting person in this filing.
Baird Medical Investment Holdings Ltd director Gabrielle Bilciu-Wolfson has filed an initial Form 3 disclosing her stake in the company. She reports beneficial ownership of 20,000 shares of Baird Medical common stock, held directly, with no specific buy or sell transaction indicated in this filing.
Baird Medical Investment Holdings Ltd filed an initial insider ownership report for Li Jie Clara, who serves as Acting Chief Financial Officer. This Form 3 excerpt lists her as a reporting person but shows no reported transactions or derivative positions in the summarized data.
Baird Medical Investment Holdings Ltd director Ragan Joseph Douglas III filed an initial Form 3 reporting his holdings in the company. The filing shows direct ownership of 57,180 BDMD shares, establishing his starting equity position as a reporting insider, with no specific buy or sell transaction disclosed.
Baird Medical Investment Holdings Ltd director Hou Wei reported initial holdings of 91,545 RSU Shares (BDMD) in a Form 3 filing. These RSU shares are listed as directly owned, and the filing records Hou Wei’s beneficial ownership position without reporting any specific buy or sell transactions.
Baird Medical Investment Holdings Ltd director and 10% owner Wu Haimei has reported a direct holding of 18,195,281 Ordinary Shares of BDMD. The Form 3 entry reflects this ownership position, with no associated buy or sell transactions indicated in the data provided.
Baird Medical Investment Holdings Limited reported a change in its independent auditor. The company dismissed Kreit & Chiu CPA LLP and appointed Guangdong Prouden CPAs GP as its new independent registered public accounting firm, effective February 10, 2026, for the year ended December 31, 2025.
Kreit & Chiu’s prior reports for the year ended December 31, 2024 contained no adverse opinions or qualifications, and the company states there were no disagreements on accounting, disclosure, or audit scope. However, the company continues to have material weaknesses in internal control over financial reporting, including insufficient U.S. GAAP/SEC-experienced staff and the absence of a comprehensive U.S. GAAP accounting policy manual and documented controls. The new auditor is aware these material weaknesses are considered a reportable event.